Tumor flare reaction associated with lenalidomide treatment in patients with chronic lymphocytic leukemia predicts clinical response. - Wikidata - awgldk - TriplyDB

Tumor flare reaction associated with lenalidomide treatment in patients with chronic lymphocytic leukemia predicts clinical response.

Tumor flare reaction associated with lenalidomide treatment in patients with chronic lymphocytic leukemia predicts clinical response.

http://www.wikidata.org/entity/Q51037241

about

Corticosteroids for the management of cancer-related pain in adults Immunotherapy in Chronic Lymphocytic Leukaemia (CLL)Lenalidomide and chronic lymphocytic leukemia Immune reconstitution in chronic lymphocytic leukemia Final results of a multicenter phase 1 study of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia.Approaches to Managing Safety With Lenalidomide in Hematologic Malignancies Safety and efficacy of different lenalidomide starting doses in patients with relapsed or refractory chronic lymphocytic leukemia: results of an international multicenter double-blinded randomized phase II trial.Lenalidomide induces long-lasting responses in elderly patients with chronic lymphocytic leukemia Lenalidomide as initial therapy of elderly patients with chronic lymphocytic leukemia.Update on immunomodulatory drugs (IMiDs) in hematologic and solid malignancies.Lenalidomide induces immunomodulation in chronic lymphocytic leukemia and enhances antitumor immune responses mediated by NK and CD4 T cells.A dose escalation feasibility study of lenalidomide for treatment of symptomatic, relapsed chronic lymphocytic leukemia Identification of outcome-correlated cytokine clusters in chronic lymphocytic leukemia Targeted treatment for chronic lymphocytic leukemia.Reduced occurrence of tumor flare with flavopiridol followed by combined flavopiridol and lenalidomide in patients with relapsed chronic lymphocytic leukemia (CLL)Lenalidomide in the treatment of chronic lymphocytic leukemia.Novel targeted agents and the need to refine clinical end points in chronic lymphocytic leukemia.Emerging role of kinase-targeted strategies in chronic lymphocytic leukemia.Ibrutinib: a paradigm shift in management of CLL.Chronic lymphocytic leukemia/small lymphocytic lymphoma, version 1.2015 Biology of chronic lymphocytic leukemia in different microenvironments: clinical and therapeutic implications.New Pharmacotherapies in Chronic Lymphocytic Leukemia.Treating chronic lymphocytic leukemia with thalidomide and lenalidomide.CAL-101: a phosphatidylinositol-3-kinase p110-delta inhibitor for the treatment of lymphoid malignancies.Comparing efficacy of reduced-toxicity allogeneic hematopoietic cell transplantation with conventional chemo-(immuno) therapy in patients with relapsed or refractory CLL: a Markov decision analysis.Lenalidomide alone and in combination for chronic lymphocytic leukemia.Emerging therapies for refractory chronic lymphocytic leukemia.Rethinking clinical response and outcome assessment in a biologic age.Microenvironment interactions and B-cell receptor signaling in Chronic Lymphocytic Leukemia: Implications for disease pathogenesis and treatment.Evolution of lymphoma staging and response evaluation: current limitations and future directions.Molecular action of lenalidomide in lymphocytes and hematologic malignancies Biological effects and clinical significance of lenalidomide-induced tumour flare reaction in patients with chronic lymphocytic leukaemia: in vivo evidence of immune activation and antitumour response.Long-term molecular remission with lenalidomide treatment of relapsed chronic lymphocytic leukemia.International Working Group consensus response evaluation criteria in lymphoma (RECIL 2017).

P2860

Q24186400-9814CD7A-DD43-45FD-B67D-FF87920899E6 Q26768154-A93ABC87-A24A-4669-8D27-72F5851EDD92 Q26823597-EC0FB1B4-C64D-48A2-ACF5-3905CD97AD5E Q26865561-9F50096C-773E-4640-A11A-6F9EC2DF45B2 Q33396918-5D4C3303-4A01-49E0-A711-BB2B275C8112 Q33423873-57992268-2F79-4962-8DF5-C8FF83F6F313 Q33429161-4889EB4A-C845-4552-910B-5C0D241889AF Q34008584-BE9731D1-5338-4E41-B7A9-F2D79B852ACF Q34009041-F97F394F-26BA-47AC-BFB4-A722599D0F5D Q34253548-45203F33-67EF-471C-8DCE-2070B596B480 Q34278096-6D2FA0C4-3161-45DE-B212-FBBBA600D6FB Q35033519-817984E9-A8B3-4655-B2EC-CF68554EEEBB Q35553576-3A2FA90C-6644-444E-BA32-68D6FC300F4B Q35599741-D308AB1B-1EEE-4E28-B5AE-C5B812788A77 Q36003724-4A4629DD-FF75-4A13-9B7E-DB047EF61F82 Q36125070-606250CD-5DEC-4F0F-ABA2-C34511027728 Q36135185-429A761F-6254-43C8-A944-DA28C437F32B Q36462375-C0046D47-B8F9-4421-90B0-8B0325BA5369 Q36739295-17F4D650-AD02-4BDF-8716-DD10FAF2D5AB Q36826893-B2158171-C36C-46CB-9071-6FADA6C62B04 Q36862781-81A6CE47-C12A-482A-A0AF-250988A68DEA Q37605306-2B67560F-B33E-414E-BA49-97B3F90B868B Q37958036-15187E6B-7191-40F7-BA7D-AEF0454A8FA4 Q37960157-415A288D-E848-4557-B936-0CBA07D75ECA Q38007853-BE5AEF22-4E8A-40AF-8892-D1DA33A9938D Q38068736-9CA52EBB-59A6-4A50-9231-388EEC3093EB Q38207143-20079F4E-75D3-462E-A9E2-E611BC061AF8 Q38480777-0F68FB14-93EC-4464-8AF1-F95A05A9067A Q38550810-ECFE9C00-3AEE-4E1D-A3D6-C8E6860476CA Q38671671-77E09C71-C913-4E95-BFC4-221954D2E6DB Q39570166-9ECCBFBB-7433-46E0-AC14-38A88A493D95 Q41356235-11FF4E67-6BEE-4747-8C9A-A8D392F6B185 Q43596419-B4A0DF0E-E5CD-4F42-8EC5-9F011351268E Q48669191-0678FC1A-FB53-47DA-BAC4-847429E94FE4

P2860

Tumor flare reaction associated with lenalidomide treatment in patients with chronic lymphocytic leukemia predicts clinical response.

http://www.wikidata.org/entity/Q51037241

description

2010 nî lūn-bûn

@nan

2010年の論文

@ja

2010年学术文章

@wuu

2010年学术文章

@zh

2010年学术文章

@zh-cn

2010年学术文章

@zh-hans

2010年学术文章

@zh-my

2010年学术文章

@zh-sg

2010年學術文章

@yue

2010年學術文章

@zh-hant

name

Tumor flare reaction associate ...... ia predicts clinical response.

@en

Tumor flare reaction associate ...... ia predicts clinical response.

@nl

type

label

Tumor flare reaction associate ...... ia predicts clinical response.

@en

Tumor flare reaction associate ...... ia predicts clinical response.

@nl

prefLabel

Tumor flare reaction associate ...... ia predicts clinical response.

@en

Tumor flare reaction associate ...... ia predicts clinical response.

@nl

P1433

Q51037241-65A935E6-C9A7-4D0E-A81A-6A374C754FF1

P1476

Q51037241-E75D8A51-6225-4873-9E05-085C26466903

P2093

Q51037241-0664C601-A1B3-4ED1-92DA-451D7C154E41

Q51037241-23B6CC34-1D32-4FC7-B3D1-D4E7909565D1

Q51037241-2A367F6D-840E-4DE2-9EA1-B9F587DFB9FB

Q51037241-49BE91F7-56B8-4E73-9DC2-42A3B5FB96A8

Q51037241-75145B48-7B5C-4706-8B66-FC74EB143102

Q51037241-8E65A7E8-7A69-4514-ADED-454513BB54FE

Q51037241-9A307A51-A474-424C-9416-67A8E46AC645

Q51037241-9B292239-20FE-46CA-8DC5-4EBB7FDB3648

Q51037241-D1BF5BBF-E30E-425F-9856-32C59F15AF2D

Q51037241-DA3B74A7-0F26-43C4-B84F-23D087507823

P2860

Q51037241-129F9962-29EE-475F-8060-141F08A41AD9

Q51037241-20A6F82F-C01D-4EB0-B816-9A7FC08ADC42

Q51037241-219A814B-91C1-4ADC-AFF7-82D5482633F7

Q51037241-3A5084DA-8407-4A97-BA08-068E2E903014

Q51037241-3AC96EB8-E01E-482F-8276-FEB90B6AD616

Q51037241-A6FC4A71-CC7B-4DBE-B5E6-0134B055CF6E

Q51037241-C9D01FBD-CC9C-4B6D-B2B5-34105FD32FD3

P304

Q51037241-7496F37C-8955-4791-A15A-73787AE50D8D

P31

Q51037241-FFD33B65-7815-4BFC-8EED-3ED7BF771957

P356

Q51037241-55B2140C-E67C-4E33-8E84-245F06EE1572

P407

Q51037241-18DC9B80-7962-4D25-8A51-89BB4189EAB5

P433

Q51037241-6B34DB5D-FAC5-4DAF-B62E-5F689D2E2B39

P478

Q51037241-57765424-0A2D-48C0-889B-E2C9AC916672

P577

Q51037241-3B2EE6E9-8A82-4BDC-82BF-2EEE781DB345

P5875

Q51037241-291FE5E5-DE25-48AF-BFB6-B013A52BAE2F

P698

Q51037241-CB435310-4832-4C78-B1BD-7DB8E13677D9

P921

Q51037241-7C2A1163-73EF-42AF-A1E5-EA290819E77E

Q51037241-B9C00910-319E-4734-88F1-0A9CAFDAC187

P356

P1433

P1476

Tumor flare reaction associate ...... ia predicts clinical response.

@en

P2093

Asher Chanan-Khan

http://www.w3.org/2001/XMLSchema#string

Austin Miller

http://www.w3.org/2001/XMLSchema#string

David Lawrence

http://www.w3.org/2001/XMLSchema#string

Francisco Hernandez-Illatazurri

http://www.w3.org/2001/XMLSchema#string

Jerome B Zeldis

http://www.w3.org/2001/XMLSchema#string

Kelvin Lee

http://www.w3.org/2001/XMLSchema#string

Kena C Miller

http://www.w3.org/2001/XMLSchema#string

Myron S Czuczman

http://www.w3.org/2001/XMLSchema#string

Paul K Wallace

http://www.w3.org/2001/XMLSchema#string

Swaminathan Padmanabhan

http://www.w3.org/2001/XMLSchema#string

P2860

Enhancement of ligand-dependent activation of human natural killer T cells by lenalidomide: therapeutic implications

Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma.

Efficacy of lenalidomide in myelodysplastic syndromes.

Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase II study.

Higher doses of lenalidomide are associated with unacceptable toxicity including life-threatening tumor flare in patients with chronic lymphocytic leukemia.

N9986: a phase II trial of thalidomide in patients with relapsed chronic lymphocytic leukemia.

Results of a phase 1 clinical trial of thalidomide in combination with fludarabine as initial therapy for patients with treatment-requiring chronic lymphocytic leukemia (CLL).

P304

2127-2135

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/CNCR.25748

http://www.w3.org/2001/XMLSchema#string

P407

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

117

http://www.w3.org/2001/XMLSchema#string

P577

2010-11-29T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51080449

http://www.w3.org/2001/XMLSchema#string

P698

21523725

http://www.w3.org/2001/XMLSchema#string

P921